Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of HLX04-O vs ranibizumab in wet Age-related Macular Degeneration
2020-005364-57Phase 3Completed
- Sponsor
- Henlius
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of HLX04-O in exudative macular degeneration (3 arms), sponsored by Henlius. Primary endpoint: Part 1 safety run-in endpoints. Started Feb 2021; status: completed.
02
Drugs
HLX04-O
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2020-005364-57.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005364-57.